NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NAMS · as of Jun 8, 2026
Key Statistics
Explore NewAmsterdam Pharma Company N.V. Data
nams stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 90.0%
The NAMS analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $49.00, representing +57.56% upside from the current price of $31.10.
Competitors & Peers
nams competitorsNAMS
ACLX
AKRO
CGON
CRNX
IMVTStock Performance
Full HistoryAbout NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib,…
what is newamsterdam pharma company n.v. · nams stock overview · newamsterdam pharma company n.v. company profile · who is newamsterdam pharma company n.v. ceo · nams NASDAQ · newamsterdam pharma company n.v. headquarters · newamsterdam pharma company n.v. business segments
About Stock Overview & Key Data
NewAmsterdam Pharma Company N.V. (NAMS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 9, 2021. As of the latest trading session, NAMS stock price is $31.10, with a market capitalization of $3.6B. The stock has returned +54.83% over the past 12 months and -11.02% year-to-date.
According to 10 Wall Street analysts, the consensus rating for NewAmsterdam Pharma Company N.V. stock is Buy, with an average 12-month price target of $49.00. In fiscal year 2025, NewAmsterdam Pharma Company N.V. reported revenue of $22.5M and net income of -$203.8M. For detailed data — including NewAmsterdam Pharma Company N.V. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, NewAmsterdam Pharma Company N.V. (NAMS) stock price is $31.10. The stock is traded on NASDAQ under the ticker symbol NAMS. The 52-week range is $17.63 – $42.20.